M: Metastasis; N: Node; T: Tumor. Data from [21]. Neuroendocrine tumors have demonstrated an increase in incidence and prevalence over the past decades, partly due to increased awareness ...

She had been diagnosed as having metastatic pulmonary neuroendocrine tumor. The patient's medical and family history was unremarkable; she had, however, smoked more than 20 cigarettes per day for ...

A three-year follow-up study of Lu-EBTATE in 30 patients with metastatic neuroendocrine tumors demonstrated a 40% reduction in administered dose compared to Lu-DOTATATE, with no kidney or liver ...

the current standard of care. Our 3-year follow up of 177 Lu-EBTATE in patients* (N=30) with metastatic neuroendocrine tumors, demonstrated good safety with no nephro- or hepatoxicity and 86% ...

Carcinoid tumor of midgut origin with large segment ... The resected mass showed signs of hemorrhage within the neuroendocrine metastasis and was associated with clear resection margins (Figure ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

On second thought, the FDA figures it no longer needs to discuss Exelixis’ application for Cabometyx in neuroendocrine tumors ...

"Our work demonstrates that castrate-resistant neuroendocrine prostate cancer relies on mitochondrial quality control to sustain tumor growth, metastatic potential and cisplatin resistance," notes ...

According to GlobalData, Phase II drugs for Neuroendocrine Tumors have a 28% phase ... or third-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).

M: Metastasis; N: Node; T: Tumor. Data from [21]. Neuroendocrine tumors have demonstrated an increase in incidence and prevalence over the past decades, partly due to increased awareness ...